PharmiWeb.com - Global Pharma News & Resources
PharmiWeb Today Story
Evotec and QIAGEN enter software collaboration for enhanced multi-omics data insights
  • Collaboration leverages synergies of QIAGEN’s OmicSoft omics data through Evotec’s analysis platform PanHunter
  • Customers accelerate target discovery decisions with high-quality multi-omic evidence, and expanded analysis capabilities

Hamburg, Germany, and Venlo, the Netherlands, 03 June 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to leverage QIAGEN’s OmicSoft Land Databases through Evotec’s PanOmics data access and analysis platform PanHunter. Combining comprehensive data sets with advanced analytics capabilities will enable enhanced multi-omics data insights, better disease understanding and more precise therapeutic interventions.

Omics data offers extensive insights into patient conditions, molecular biology, and disease causes. QIAGEN’s market-leading OmicSoft solution accelerates research discoveries in biotech and pharma with vast amounts of annotated Omics data. QIAGEN’s OmicSoft Land Databases comprise integrated collections of multi-omics data and metadata, so-called “Lands”, which have been curated and standardised from the largest public dataset repositories. Through these deeply-curated and unified datasets, data scientists avoid common pitfalls of data mining, and can focus on powerful target profiling and indication expansion efforts.

PanHunter is Evotec’s interactive, collaborative, and easy-to-use analysis software for biological data. The next-generation platform combines published and peer-reviewed or in-house developed st…

Read More...
Evotec and QIAGEN enter software collaboration for enhanced multi-omics data insights

Articles